Upton

Researchers are evaluating infliximab, a drug that blocks tumor necrosis factor alpha TNF-b1, to treat adults with acute pancreatitis, a severe inflammation of the pancreas causing pain and organ complications. This Phase 2b trial aims to assess the effectiveness and safety of infliximab in reducing inflammation and improving outcomes in this condition. The study uses a randomized, double-blind, placebo-controlled design at multiple centers. Participants are randomly assigned to one of three groups one receives a single intravenous infusion of infliximab at 5 mgkg, another group receives a higher dose of 10 mgkg infliximab, and the third group receives a placebo infusion of saline. The infusion is given over two hours, with the dosage adjusted for body weight. The higher dose arm was discontinued partway through the trial. This treatment is given once early after diagnosis. During the study, participants will be monitored with blood tests for inflammation markers like C-reactive protein CRP, pain assessments, organ function scores, and other health outcomes up to 90 days after admission. Researchers will also track safety signals, medication levels, antibody response, hospital stay length, and quality of life. Follow-up includes multiple visits for clinical evaluation and biomarker collection to assess treatment impact and participant health.

This research aims to collect and analyze information about babies born at 22 weeks of pregnancy in the UK to better understand their clinical care and outcomes. Since survival-focused care for these extremely premature babies has only been offered since 2019, there is limited data on how they respond to treatment and what challenges they face. The study gathers data from multiple neonatal intensive care units NICUs across the UK to improve knowledge for future care and support families. Data collection involves medical staff entering selected, anonymized information from babies medical records into a secure database. The study observes babies who are attended by neonatal teams at birth or admitted to NICUs within the first 72 hours of life. No changes are made to the babies care during the study, and a one-time survey of NICUs will assess unit approaches and equipment used for 22-week babies. Participants data, including clinical care details and short-term outcomes such as survival to discharge, are analyzed. Researchers will report on interventions across various care areas and outcomes like brain injury or infections. Parents receive information about data use, and individual babies cannot be identified in results. The study runs from admission until death or discharge from neonatal care, aiming to inform future research and improve care practices.